Background: Invasive fungal infections (IFIs) are considered a major problem among patients undergoing acute leukaemia (AL) induction treatment. PROphylaxis of Fungal invasive Infections in Leukaemia-Caspofungin (PROFIL-C) is a multicentre study aiming to assess the comparative yield of using caspofungin versus standard policy (SP) regimens and the overall impact of IFI in routine clinical care conditions.
Introduction
The need for antifungal prophylaxis to prevent invasive fungal infections (IFIs) in haematological patients is still debatable, considering its potential role in inducing resistant strains and impairing the diagnostic accuracy of Aspergillus galactomannan (GM) antigen detection and its cost -efficacy ratio. 1, 2 On the other hand, a recent meta-analysis 3 showed a reduction of mortality among cancer patients receiving antifungal prophylaxis. Patients with acute myeloid leukaemia (AML) 4 -6 are specifically considered for targeted antifungal prophylaxis because of the higher incidence of IFI and particularly invasive aspergillosis (IA) during induction chemotherapy. 7 -10 The efficacy of anti-Aspergillus azole prophylaxis, including itraconazole and posaconazole, may be reduced by inadequate plasma levels due to impaired gastrointestinal absorption as a result of mucositis or food interactions and interaction with concomitant drugs. The interest of focusing on caspofungin as a prophylactic agent was motivated by its spectrum of action against Candida spp. and Aspergillus spp., its safety record and the lack of interaction with the metabolism of other drugs. The safety and tolerability of caspofungin have been proven both as empirical therapy during neutropenia by Walsh et al. 11 and as primary prophylaxis in patients undergoing haematopoietic stem cell transplantation (HSCT) by Chou et al.
12
PROphylaxis of Fungal invasive Infections in LeukaemiaCaspofungin (PROFIL-C) is a multicentre study aiming to assess the efficacy and safety of caspofungin as prophylaxis for pulmonary IA in patients undergoing induction treatment for newly diagnosed acute leukaemia (AL) and the overall impact of IFIs in routine clinical conditions of care.
Patients and methods

Trial design
The PROFIL-C study was implemented from January 2007 to January 2009 as a multicentre Phase II parallel group study with a randomized comparison (1:1) between caspofungin and standard policy (SP) regimens. The study was registered at http://www.clinicaltrial.gov (NCT00501098).
Participants
All consecutive patients aged ≥18 years with de novo acute lymphoblastic leukaemia (ALL) or AML were registered into PROFIL-C at the start of induction chemotherapy, after giving their informed consent. Patients were not considered eligible if they had signs or symptoms of suspected IFI at enrolment, history of hypersensitivity to echinocandin, acute hepatitis or moderate/severe hepatic insufficiency. Other exclusion criteria were concomitant treatment with any systemic antifungal therapy or recent prior use of caspofungin and pregnancy or breast-feeding.
The protocol and the consent form were approved by the Ethics Committee of each of the eight participating institutions, who belong to the network of Haematological Units of the Northern Italy Leukaemia Group (NILG); data were collected by the Mario Negri Sud Institute.
Interventions
Patients were randomized using a central assignment system to an intervention group, given caspofungin 70 mg/day and 50 mg/day intravenously until protocol endpoints were reached, i.e. either leukaemia remission or the occurrence of IFI or a severe adverse event, and to a control group treated with SP prophylaxis according to the physician's decision.
The switch to a systemic antifungal therapy was the decision of the investigator.
Patients affected by ALL underwent induction therapy according to NILG-ALL 09/00 protocol 13 intravenously twice daily days 1, 2, 8 and 9, idarubicin 18 mg/m 2 intravenously days 3 and 10; 60-65 years, doses of Ara-C 1-2 g/m 2 according to the decision of each centre).
GM antigen detection was performed twice weekly. Antibacterial prophylaxis, consisting of levofloxacin 500 mg/day, was administered to all patients. Topical antifungal therapy and antiviral prophylaxis were also permitted, according to each centre's SP. At the onset of fever, all patients underwent blood and urine culture examination, chest X-ray and culture of any other fluid/drainage obtained from a suspected infection site. CT scan of the thorax was performed when fever persisted .48 h. When a pulmonary infiltrate was present, without evidence of a microbiological isolate from cultural or serological tests, a bronchoalveolar lavage (BAL) was performed. IFIs were defined according to the criteria of the EORTC/MSG study group. 16 Reanalysis of data according to the new diagnostic criteria 17 was also performed.
Outcomes
Primary outcome measures included the incidence of probable/proven IFIs in an unselected cohort of patients at high risk for IFI. Secondary outcome measures included the death rate related to IFIs and the efficacy -safety profile of prophylactic regimens using different antifungal agents (caspofungin versus SP-based regimens).
Death was attributed to IFI in patients who did not respond to therapy (i.e. who had stable disease or disease progression at the time of death) and in patients with a partial response to therapy who died as the result of an acute event involving any of the sites of infection.
WHO grade .2 toxicity with a possible relationship with caspofungin or SP prophylaxis was reported.
Sample size
By comparing .160 patients the study had a 80% power of detecting a 15% difference in the incidence of proven/probable IFI at a P¼0.05 significance level among the two groups. The sample size was appropriate, considering the possibility of reducing the frequency of IFI among patients with AML and ALL from 20% (according to our previous experience) 6 to 5% with caspofungin prophylaxis.
Randomization
For allocation of the participants, a computer-generated list of random numbers was used through a web-based procedure by the Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud. The detail of the series was unknown to any of the investigators.
Statistical analysis
Patients' baseline characteristics were reported as proportions (percentages) and median (interquartile range) for categorical and continuous variables, respectively. Moreover, patient characteristics according to the caspofungin prophylaxis and SP were compared using Fisher's exact test and x 2 test for categorical variables and Mann-Whitney U-test for continuous variables.
P values ,0.05 were considered statistically significant. All analyses were performed using SPSS 10.0 (SPSS Inc., Chicago, IL, USA), File Maker Pro Advanced 8.5 and SAS Statistical Package Release 9.1 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
One hundred and seventy-five patients (138 AML and 37 ALL) met the inclusion criteria and agreed to participate in the PROFIL-C protocol (Figure 1 ). Their baseline characteristics are summarized in Table 1. Table 1 also summarizes the baseline characteristics according to the assigned prophylactic regimens. Local SP included oral itraconazole (67), fluconazole (10), posaconazole (1) and no prophylaxis (4) .
Age was the only parameter that significantly differed between subgroups.
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Comparative assessment of caspofungin and SP prophylaxis (Table 3) . Possible IFIs were localized to the lung in all cases, except one possible sinus mycosis and one possible mycotic pharyngeal abscess (Table 4) .
The incidence of IFIs was not influenced by the type of chemotherapy administered in AML patients. The incidence was 18/88 (20.5%) after ICE compared with 11/50 (22.0%) after the more aggressive HDS-1/2 induction (P ¼ 0.83). There were no differences between ALL 09/00 and ALL 10/07 induction treatments.
Using the new diagnostic criteria for IFIs, 17 the number of proven/probable IFIs and IAs found did not change, whereas the incidence of possible IFIs and IAs was reduced from 12.6% to 8.6% and from 11.4% to 7.4%, respectively.
Outcome of IFIs/IAs
Fifteen of the 175 (8.6%, 95% CI 4.4 -12.8) patients died (caspofungin: 9.7%; SP prophylaxis: 7.3%) (RR 1.32, 95% CI 0.49 -3.56). In only one case, G. capitatum sepsis, was death attributable to probable/proven IFI. None of the eight patients with probable/ proven IA died. Other causes of death included septic shock (five cases), cerebral haemorrhage (four cases), progressive disease (three cases), possible mycotic sinusitis (one case) and possible pulmonary aspergillosis (one case).
Safety of caspofungin
None of the patients receiving caspofungin died of toxicity, whereas one patient receiving itraconazole died of hepato-renal failure, possibly due to prophylaxis-related toxicity. Globally, five patients experienced WHO grade .2 toxicity (three hepatic, one skin, and one hepatic and renal), with three receiving caspofungin and two itraconazole.
Discussion
Despite the general consensus on the great clinical relevance of IFIs in the overall management of AL patients, both in terms of morbidity and mortality, the cost-effectiveness of antifungal prophylaxis is not fully elucidated. The retrospective nature of many studies and the selected patient populations enrolled in prospective studies 18 do not allow a generalization of their results to routine clinical practice.
The use of anti-Aspergillus prophylaxis in AL patients was SP at most NILG centres, with ,5% of patients at one single hospital not considered for prophylaxis. Oral itraconazole was the antifungal drug most frequently used. In spite of recent guidelines 8, 19 based on the results of randomized studies, 20 In PROFIL-C the clinical approach of nearly universal antifungal prophylaxis during induction treatment of AL was associated with a very low incidence of proven/probable IFIs (particularly IA). Figures were higher in other studies; 4, 5 however, data were retrospective and referred to somewhat different haematological populations.
The small number of outcome events makes it difficult to associate statistical significance with the differences found between percentages. The incidence of proven/probable IA was 5.4% in the caspofungin group compared with 3.7% in patients receiving standard prophylaxis with azoles. While the use of mould-active azoles may reduce the sensitivity of GM detection, 22 it is known that echinocandins may paradoxically increase GM levels by inducing hyphal fragmentation 23 and do not negatively affect such an important diagnostic tool. When including possible IFI in the comparison, a condition where strong clinical suspicion of IFI is not formally supported by microbiological evidence of mycosis, patients receiving caspofungin had a lower incidence of IFI compared with patients receiving standard prophylaxis; however, this difference did not reach statistical significance. The cumulative incidence of IFI remained lower with caspofungin, even considering the more stringent 2008 international MSG/EORTC diagnostic criteria of possible IFI, 17 which should better identify real cases of IFI and actually reduced by approximately one-third the number of possible IFIs in PROFIL-C. As a matter of fact, these results show that IFIs, and particularly IA, may at present have less of an impact in patients with AL, even among those treated with more intensive regimens.
Matiuzzi et al. 24 reported the results of a single-institution Phase III study comparing caspofungin with itraconazole during induction. Also in this study, the incidence of events was similar in both arms, but more patients in the itraconazole group were dropped from the study because of drug-related adverse events. In PROFIL-C, with the limitation of a relatively small number of patients, the results obtained in the subgroup randomized to caspofungin seem to support the favourable characteristic of this drug, whose profile in real practice was one of the explicit targets of the study. Considering its efficacy together with its low interaction rate with other drugs and its tolerability, it can be included among antimycotic agents that can be used as an alternative in patients undergoing induction treatment for AL.
In conclusion, the PROFIL-C study showed that caspofungin prophylaxis was effective and well tolerated, although it did not show a statistically significant advantage compared with the standard antifungal prophylactic policy adopted by participating centres. It may be particularly suited for patients at risk of impaired intestinal drug absorption and for those with severe hepatic and renal dysfunction. Oral antifungal prophylaxis with azoles is currently the most common practice in large NILG haematological centres during induction treatment of AL. In this context, the frequency of IFI/IA was lower than expected based on recent epidemiological surveys.
